Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting

被引：0
|
作者：
Ray, J. A.
Valentine, W. J.
Goodall, G.
Aagren, M.
Kotchie, R. W.
机构：
[1] IMS Hlth, Hlth Econ Dept, Basel, Switzerland
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[3] IMS Hlth, Hlth Econ Dept, London, England
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1033
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN SPAIN
    Ramirez de Arellano, A.
    Lizan, L.
    Prades, M.
    Morales, C.
    De Luis, D.
    VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
  • [32] Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes
    Raslová, K
    Bogoev, M
    Raz, I
    Leth, G
    Gall, MA
    Hancu, N
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) : 193 - 201
  • [33] Switching from basal-bolus therapy with NPH insulin to basal-bolus therapy with the analog insulin detemir improves glycemic control and reduces hypoglycemic episodes, without weight gain, in type 1 and type 2 diabetes patients: Results from German subgroup of the PREDICTIVE study
    Ruhnau, Klaus-Juergen
    Hansen, Jes B.
    Dornhorst, Anne
    DIABETES, 2006, 55 : A133 - A133
  • [34] Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes
    Nimri, Revital
    Lebenthal, Yael
    Shalitin, Shlomit
    Benzaquen, Hadasa
    Demol, Sharon
    Phillip, Moshe
    PEDIATRIC DIABETES, 2013, 14 (03) : 196 - 202
  • [35] Quality of life (QoL) assessment of insulin detemir and NPH human insulin in Japanese subjects with diabetes on basal-bolus regimen
    Ishii, Hitoshi
    Iwamoto, Yasuhiko
    Kaku, Kohei
    Kawamori, Ryuzo
    Tajima, Naoko
    Kobayashi, Masashi
    DIABETES, 2007, 56 : A710 - A710
  • [36] Institution of Basal-Bolus Therapy at Diagnosis for Children With Type 1 Diabetes Mellitus
    Adhikari, Soumya
    Adams-Huet, Beverley
    Wang, Yu-Chi A.
    Marks, James F.
    White, Perrin C.
    PEDIATRICS, 2009, 123 (04) : E673 - E678
  • [37] Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in a German setting. A modeling evaluation based upon results from a meta-analysis
    Kotchie, R.
    Scheijbeler, H.
    Aagren, M.
    Nielsen, S.
    Valentine, W. J.
    Goodall, G.
    VALUE IN HEALTH, 2007, 10 (06) : A222 - A222
  • [38] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
    Sellam, Y.
    Malek, R.
    Semrouni, M.
    Belhadj, M.
    Zekri, S.
    Brouri, M.
    Arbouche, Z.
    Nouri, N.
    VALUE IN HEALTH, 2020, 23 : S511 - S511
  • [39] OPTIMAL REGIMENS OF THE BASAL-BOLUS INSULIN THERAPY IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
    Galkina, G. A.
    Voropay, A. A.
    Levkovich, M. A.
    Vorobiov, S. V.
    Komkova, M. V.
    Morozova, N. V.
    BYULLETEN SIBIRSKOY MEDITSINY, 2015, 14 (05): : 15 - U223
  • [40] Visceral fat mass in patients with Type 2 diabetes is reduced during insulin Detemir-based basal bolus therapy, whereas it is increased during NPH-insulin-based basal bolus therapy
    Tinahones, Francisco Jose
    Martin, Miguel
    Cardona, Fernando
    Macias-Gonzalez, Manuel
    OBESITY AND METABOLISM-MILAN, 2008, 4 (03): : 165 - 168
12345